Watanabe Shinichi, Takahashi Hisashi, Nishikawa Takeji, Takiuchi Iwao, Higashi Nobuhiko, Nishimoto Katsutaro, Kagawa Saburo, Yamaguchi Hideyo, Ogawa Hideoki
Department of Dermatology, Teikyo University School of Medicine, Itabashi, Japan.
Mycoses. 2006 May;49(3):236-41. doi: 10.1111/j.1439-0507.2006.01218.x.
The aim of the study was to compare the efficacy and safety of luliconazole 1% cream and bifonazole 1% cream as applied in the treatment of tinea pedis (interdigital-type and plantar-type). A multi-clinic, randomised single-blind, parallel group study with 34 hospitals and 11 clinics formed the study design. Five hundred and eleven patients with mycologically confirmed tinea pedis were included. Of the 489 evaluable patients, 247 were randomised to luliconazole, and 242 to bifonazole. Luliconazole 1% cream applied once a day for 2 weeks, followed by a placebo cream for 2 weeks, thereafter. Bifonazole 1% cream applied once a day for 4 weeks. Mycological effect (negative result on microscopy) and improvement of skin lesions were measured at weeks 1, 2, 3 and 4. Safety frequency and severity of adverse reactions were also measured. The improvement of skin lesions after 4 weeks was comparably good with rates of 91.5% vs. 91.7% (luliconazole vs. bifonazole). The mycological effect was characterised by high negative rates of 76.1% vs. 75.9% (luliconazole vs. bifonazole). The progression of tinea-related signs and symptom scores differed insignificantly between evaluated luliconazole and bifonazole treatment groups comprising a total of 500 patients. Both substances appeared to be comparably safe and well-tolerated.
本研究旨在比较1%卢立康唑乳膏和1%联苯苄唑乳膏治疗足癣(指间型和跖型)的疗效和安全性。该研究设计为一项多中心、随机单盲、平行组研究,涉及34家医院和11家诊所。纳入了511例经真菌学确诊的足癣患者。在489例可评估患者中,247例随机分配至卢立康唑组,242例随机分配至联苯苄唑组。1%卢立康唑乳膏每天涂抹一次,持续2周,之后使用安慰剂乳膏2周。1%联苯苄唑乳膏每天涂抹一次,持续4周。在第1、2、3和4周测量真菌学效果(显微镜检查结果为阴性)和皮肤病变的改善情况。还测量了不良反应的安全频率和严重程度。4周后皮肤病变的改善情况相当良好,卢立康唑组与联苯苄唑组的改善率分别为91.5%和91.7%。真菌学效果的特征是阴性率较高,卢立康唑组与联苯苄唑组分别为76.1%和75.9%。在总共500例患者的评估中,卢立康唑和联苯苄唑治疗组之间足癣相关体征和症状评分的进展差异不显著。两种药物似乎安全性相当且耐受性良好。